Novel characterisation of mast cell phenotypes from peripheral blood mononuclear cells in chronic fatigue syndrome/myalgic encephalomyelitis patients.
Nguyen, Thao, Johnston, Samantha, Chacko, Anu et al. · Asian Pacific journal of allergy and immunology · 2017 · DOI
Quick Summary
This study looked at immune cells called mast cells in the blood of people with ME/CFS and compared them to healthy people. Researchers found that ME/CFS patients—especially those with severe illness—had more mast cells and these cells showed different activation patterns. Mast cells are known to release chemicals that cause inflammation, so understanding them better could help explain some ME/CFS symptoms.
Why It Matters
Mast cells release multiple inflammatory mediators implicated in ME/CFS symptomatology, and identifying abnormal mast cell phenotypes provides potential biological markers for understanding disease mechanisms. These findings could eventually support development of targeted therapies if mast cell dysfunction is confirmed as causally relevant to ME/CFS pathology.
Observed Findings
Significant increase in naïve mast cells (CD117+CD34+FCεRI-chymase-) in moderate and severe CFS/ME patients compared to healthy controls.
Significant increase in CD40 ligand expression on differentiated mast cells in severe CFS/ME versus controls and moderate CFS/ME.
Significant increase in MHC-II receptor expression on differentiated mast cells in severe CFS/ME compared to controls and moderate CFS/ME.
No significant differences in plasma HMGB1 or soluble RAGE levels between groups.
Inferred Conclusions
Peripheral mast cells show abnormal phenotypic profiles in CFS/ME, particularly accumulation of naïve populations in moderate-to-severe disease.
Mast cell activation markers and antigen-presenting capacity are elevated in severe CFS/ME, suggesting heightened inflammatory potential.
Mast cell dysfunction may contribute to CFS/ME pathophysiology, though a causal relationship remains to be established.
Remaining Questions
Do these mast cell phenotypic abnormalities directly cause or contribute to specific ME/CFS symptoms such as fatigue, post-exertional malaise, and immune dysfunction?
Are the observed mast cell changes stable biomarkers of disease severity, or do they fluctuate with disease activity and symptom severity?
What This Study Does Not Prove
This study does not prove that mast cell abnormalities cause ME/CFS symptoms, only that they are associated with the disease. The research also does not establish whether these mast cell changes are primary drivers of pathology or secondary consequences of the illness. Long-term follow-up and functional studies are needed to determine clinical significance.
What functional consequences result from the increased naïve mast cells and elevated activation markers—do they produce different cytokine/mediator profiles than control cells?
Could mast cell-targeted therapies ameliorate ME/CFS symptoms, and are certain patient subgroups more likely to benefit based on mast cell phenotype?